High-Cost Users of Prescription Drugs: National Health Insurance Data from South Korea

Park, Dahye; Lee, Hye Yeong; Kim, Dong‐Sook

doi:10.1007/s11606-021-07165-x

Cited by 4 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found that sex and age were associated with drug exposure, which may have affected the benefits of genotyping. Elderly patients (≥65 years) can be mostly benefited from genotyping, which is consistent with the tendency of high‐cost users of prescription drugs 23 . The benefit of pre‐emptive genotyping was similarly emphasized in the elderly due to polypharmacy 24,25 .…”

Section: Discussionsupporting

confidence: 63%

“…Elderly patients (≥65 years) can be mostly benefited from genotyping, which is consistent with the tendency of high‐cost users of prescription drugs. 23 The benefit of pre‐emptive genotyping was similarly emphasized in the elderly due to polypharmacy. 24 , 25 Additionally, the frequency of high‐risk phenotypes can be a crucial factor in estimating costs.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Estimation of the benefit from pre‐emptive genotyping based on the nationwide cohort data in South Korea

Huh,

Hwang,

et al. 2024

Clinical Translational Sci

View full text Add to dashboard Cite

Genetic variants affect drug responses, making pre‐emptive genotyping crucial for averting serious adverse events (SAEs) and treatment failure. However, assessing the benefits of pre‐emptive genotyping based on genetic distribution, drug exposure, and demographics is challenging. This study aimed to estimate the population‐level benefits of pre‐emptive genotyping in the Korean population using nationwide cohort data. We reviewed actionable gene‐drug combinations recommended by both the Clinical Pharmacogenomics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) as of February 2022, identifying high‐risk phenotypes. We collected reported risk reduction from genotyping and standardized it into population attributable risks. Healthcare reimbursement costs for SAEs and treatment failures were obtained from the Health Insurance Review and Assessment Service Statistics in 2021. The benefits of pre‐emptive genotyping for a specific group were determined by multiplying drug exposure from nationwide cohort data by individual genotyping benefits. We identified 31 gene‐drug‐event pairs, with CYP2D6 and CYP2C19 demonstrating the greatest benefits for both male and female patients. Individuals aged 65–70 years had the highest individual benefit from pre‐emptive genotyping, with $84.40 for men and $100.90 for women. Pre‐emptive genotyping, particularly for CYP2D6 and CYP2C19, can provide substantial benefits.

show abstract

Section: Discussionsupporting

confidence: 63%

Section: Discussionmentioning

confidence: 99%

Estimation of the benefit from pre‐emptive genotyping based on the nationwide cohort data in South Korea

Huh,

Hwang,

et al. 2024

Clinical Translational Sci

View full text Add to dashboard Cite

show abstract

“…In Korea, the NHI covers 97% of the Korean population, and claims data are submitted to the Health Insurance Review and Assessment Service. The claims data include patients' demographic characteristics, as well as the diagnosis code of the disease, the international non‐proprietary name of each drug, the prescribed dose per day, and the number of days of therapy 19,20 . The study population was a cohort of elderly patients (65 years or older) who received at least one outpatient prescription between January and December 2018.…”

Section: Methodsmentioning

confidence: 99%

“…The claims data include patients' demographic characteristics, as well as the diagnosis code of the disease, the international non‐proprietary name of each drug, the prescribed dose per day, and the number of days of therapy. 19 , 20 The study population was a cohort of elderly patients (65 years or older) who received at least one outpatient prescription between January and December 2018. We defined the index date as the first outpatient visit, the history period as 1 year before the index date, and the observation period as extending from the index date to 1 year after the index date.…”

Section: Methodsmentioning

confidence: 99%

Factors related to polypharmacy and hyper‐polypharmacy for the elderly: A nationwide cohort study using National Health Insurance data in South Korea

Cho

Chae

Yoon

et al. 2022

Clinical Translational Sci

Self Cite

View full text Add to dashboard Cite

Polypharmacy may cause adverse health outcomes in the elderly. This study examined the prevalence of continuous polypharmacy and hyper‐polypharmacy, factors associated with polypharmacy, and the most frequently prescribed medications among older adults in South Korea. This was a retrospective observational study using National Health Insurance claims data. In total, 7,358,953 Korean elderly patients aged 65 years and older were included. Continuous polypharmacy and hyper‐polypharmacy were defined as the use of ≥5 and ≥10 medications, respectively, for both ≥90 days and ≥180 days within 1 year. A multivariate logistic regression analysis was conducted with adjustment for general characteristics (sex, age, insurance type), comorbidities (12 diseases, number of comorbidities, and Elixhauser Comorbidity Index [ECI] classification), and healthcare service utilization. Among 7.36 million elderly patients, 47.8% and 36.9% had polypharmacy for ≥90 and ≥180 days, and 11.9% and 7.1% of patients exhibited hyper‐polypharmacy for ≥90 and ≥180 days, respectively. Male sex, older age, insurance, comorbidities (cardio‐cerebrovascular disease, diabetes mellitus, depressive disorder, dementia, an ECI score of ≥3), and healthcare service utilization were associated with an increased probability of polypharmacy. The therapeutic class with the most prescriptions was drugs for acid‐related disorders (ATC A02). The number of outpatient visit days more strongly influenced polypharmacy than hospitalizations and ED visits. This study provides health policymakers with important evidence about the critical need to reduce polypharmacy among older adults.

show abstract

Statins and the risk of gastric, colorectal, and esophageal cancer incidence and mortality: a cohort study based on data from the Korean national health insurance claims database

Kim

Ahn

2022

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

High-Cost Users of Prescription Drugs: National Health Insurance Data from South Korea

Cited by 4 publications

References 17 publications

Estimation of the benefit from pre‐emptive genotyping based on the nationwide cohort data in South Korea

Estimation of the benefit from pre‐emptive genotyping based on the nationwide cohort data in South Korea

Factors related to polypharmacy and hyper‐polypharmacy for the elderly: A nationwide cohort study using National Health Insurance data in South Korea

Statins and the risk of gastric, colorectal, and esophageal cancer incidence and mortality: a cohort study based on data from the Korean national health insurance claims database

Contact Info

Product

Resources

About